

Chandra P Belani

List of Publications by Citations

Source: <https://exaly.com/author-pdf/23730/chandra-p-belani-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

8,807

citations

28

h-index

64

g-index

64

ext. papers

9,720

ext. citations

5.9

avg, IF

5.36

L-index

#	Paper	IF	Citations
62	Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2002 , 346, 92-8	59.2	4300
61	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet, The</i> , 2009 , 374, 1432-40	40	926
60	Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3016-24	2.2	780
59	Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5570-7	2.2	403
58	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. <i>Oncologist</i> , 2008 , 13 Suppl 1, 5-13	5.7	262
57	Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 56-62	2.2	224
56	Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. <i>Cancer</i> , 2001 , 92, 2639-47	6.4	219
55	Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. <i>Cancer</i> , 1994 , 73, 2087-98	6.4	187
54	Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2933-9	2.2	182
53	Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). <i>Cancer</i> , 2005 , 104, 2766-74	6.4	120
52	Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 468-73	2.2	114
51	Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. <i>Lancet Oncology, The</i> , 2012 , 13, 292-9	21.7	73
50	State-of-the-art chemotherapy for advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2004 , 31, 68-74	5.5	70
49	A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 3456-61	12.9	61
48	Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. <i>Cancer</i> , 2008 , 113, 2512-7	6.4	59
47	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 570-7	4.6	58
46	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1119-1136	8.9	51

45	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48
44	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. <i>Cancer Investigation</i> , 2012 , 30, 433-46	2.1	47
43	Volociximab in cancer. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 251-7	5.4	45
42	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). <i>Cancer</i> , 2016 , 122, 2371-8	6.4	44
41	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 56233-56240	3.3	43
40	Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. <i>PLoS ONE</i> , 2015 , 10, e0118210	3.7	43
39	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1434-1448	8.9	42
38	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2014 , 14, 290	4.8	39
37	Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-41	2.2	36
36	Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2013 , 14, 557-63	4.6	33
35	Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. <i>Cancer</i> , 2008 , 113, 542-6	6.4	31
34	The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. <i>Cancer Investigation</i> , 2010 , 28, 413-23	2.1	28
33	Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. <i>Clinical Cancer Research</i> , 2010 , 16, 2496-504	12.9	27
32	Taxanes for advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1693-709	4	22
31	Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. <i>Proteomics</i> , 2015 , 15, 3267-77	4.8	16
30	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. <i>Cancer Investigation</i> , 2010 , 28, 413-423	2.1	16
29	Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 240-4	8.9	14
28	Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 464, 221-228	3.4	12

27	Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. <i>Cancer</i> , 2010 , 116, 1344-9	6.4	12
26	Pulmonary Rehabilitation in Lung Cancer. <i>PM and R</i> , 2016 , 8, 990-996	2.2	12
25	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , 2019 , 20, 484-493.e6	4.9	11
24	Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. <i>Lung Cancer</i> , 2019 , 131, 58-61	5.9	11
23	Phase I study of veliparib in combination with gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 631-643	3.5	9
22	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018 , 132, LBA-1-LBA-1	2.2	9
21	Tid1, the Mammalian Homologue of Drosophila Tumor Suppressor Tid56, Mediates Macroautophagy by Interacting with Beclin1-containing Autophagy Protein Complex. <i>Journal of Biological Chemistry</i> , 2015 , 290, 18102-18110	5.4	8
20	A phase I study of DMS612, a novel bifunctional alkylating agent. <i>Clinical Cancer Research</i> , 2015 , 21, 721-729	2.9	7
19	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2499-2511	3.8	7
18	Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients. <i>Journal of Applied Biobehavioral Research</i> , 2017 , 22, e12065	1.7	7
17	Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?. <i>Frontiers in Oncology</i> , 2014 , 4, 37	5.3	7
16	Targeted immunotherapy for non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014 , 5, 39-47	5.5	7
15	Absolute Quantification of All Identified Plasma Proteins from SWATH Data for Biomarker Discovery. <i>Proteomics</i> , 2019 , 19, e1800135	4.8	7
14	EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0217657	3.7	3
13	Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 685-97	4	3
12	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1727-1737	8.9	3
11	Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. <i>Lung Cancer</i> , 2018 , 115, 121-126	5.9	2
10	Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer. <i>PLoS ONE</i> , 2021 , 16, e0260988	3.7	2

9	Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives. <i>Current Molecular Pharmacology</i> , 2016 , 9, 183-195	3.7	2
8	Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 141, 97-100	5.9	1
7	A rewiring model of intratumoral interaction networks. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 45-51	6.8	1
6	Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. <i>European Urology Focus</i> , 2018 , 4, 94-97	5.1	0
5	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 721	3.5	0
4	A patient with complex multiple genomic ALK alterations. <i>Thorax</i> , 2016 , 71, 383-5	7.3	
3	Management of lung cancer in older adults110-123		
2	Meaningful Subset Analyses Contribute to Optimal Patient Care. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2064-2065	2.2	
1	Antiangiogenic therapy for non-small-cell lung cancer: patient selection and clinical outcomes 2013 , 178-191		